The principal U.S. patents covering NanoStatTM – NanoBio’s proprietary vaccine adjuvant technology platform – have been granted. This effectively protects NanoBio’s mucosal vaccine formulations and applications.
NanoBio Corporation’s technology is both broadly and narrowly protected by composition and method claims reflected in 19 issued U.S. patents and over 30 issued international patents, as well as numerous pending CIP and new patent filings. The issued U.S. patents provide protection up through 2030 for the company’s mucosal vaccines.
NanoBio’s patent counsel is Foley & Lardner, LLP, located in Washington, DC.